DeepMed Research

GENENTECH, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1976-01-01

Employees: 11.1K

Market Cap: -

Website: http://www.gene.com

Clinical Trials

A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Crenezumab

First Posted Date: 2013-12-02

Last Posted Date: 2024-07-30

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 252

Registration Number: NCT01998841

Locations: 🇨🇴
Grupo Neurociencias de Antioquia, Medellin, Colombia
🇨🇴
Hospital San Juan de Dios, Yarumal, Colombia
🇨🇴
Clínica de Marly, Bogota, Colombia

and more 1 locations

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: DNIB0600A
Drug: Bevacizumab

First Posted Date: 2013-11-26

Last Posted Date: 2017-10-04

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 41

Registration Number: NCT01995188

Locations: 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸
The Sarah Cannon Research Inst, Nashville, Tennessee, United States
🇺🇸
Dana Farber Cancer Inst., Boston, Massachusetts, United States

and more 1 locations

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Phase 1

Completed

Conditions: Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma

Interventions: Drug: GDC-0853

First Posted Date: 2013-11-25

Last Posted Date: 2022-06-21

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 24

Registration Number: NCT01991184

Locations: 🇺🇸
Oregon Health Sciences Uni, Portland, Oregon, United States
🇦🇺
Linear Clinical Research Limited, Nedlands, Western Australia, Australia
🇺🇸
Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, United States

and more 7 locations

A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: DNIB0600A
Drug: PLD

First Posted Date: 2013-11-25

Last Posted Date: 2017-08-21

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 95

Registration Number: NCT01991210

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
University of California Irvine Medical Center, Orange, California, United States
🇵🇱
Wojskowy Instytut Medyczny Centralny Szpital Kliniczny MON, Warszawa, Poland

and more 33 locations

A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Non Hodgkin

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Obinutuzumab
Drug: Polatuzumab Vedotin
Drug: Prednisolone
Drug: Prednisone
Drug: Rituximab

First Posted Date: 2013-11-25

Last Posted Date: 2023-03-14

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 85

Registration Number: NCT01992653

Locations: 🇫🇷
Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France
🇺🇸
Banner MD Anderson Cancer Center, Greeley, Colorado, United States
🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 8 locations

A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria

Phase 2

Completed

Conditions: Urticaria

Interventions: Drug: Placebo
Drug: Quilizumab

First Posted Date: 2013-11-20

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 32

Registration Number: NCT01987947

A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Cobimetinib
Drug: MEHD7945A

First Posted Date: 2013-11-18

Last Posted Date: 2016-07-18

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 23

Registration Number: NCT01986166

A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model

Phase 2

Completed

Conditions: Healthy Volunteer

Interventions: Drug: MHAA549A
Drug: Placebo
Drug: oseltamivir [Tamiflu]

First Posted Date: 2013-11-11

Last Posted Date: 2017-03-09

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 101

Registration Number: NCT01980966

Locations: 🇬🇧
Retroscreen Ltd, London, United Kingdom

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: GDC-0032 Phase III Tablet
Drug: GDC-0032 Tablet
Drug: GDC-0032 Capsule

First Posted Date: 2013-11-11

Last Posted Date: 2017-02-01

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 76

Registration Number: NCT01980953

Locations: 🇺🇸
Covance Research Unit - Dallas, Dallas, Texas, United States

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: GDC-0032

First Posted Date: 2013-10-23

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 15

Registration Number: NCT01967966

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy